EFFECT OF BODY IRON STORES ON SERUM ALUMINUM LEVEL IN HEMODIALYSIS-PATIENTS

被引:28
作者
HUANG, JY [1 ]
HUANG, CC [1 ]
LIM, PS [1 ]
WU, MS [1 ]
LEU, ML [1 ]
机构
[1] CHANG GUNG MEM HOSP,CHANG GUNG MED COLL,DIV NEPHROL,TAIPEI,TAIWAN
来源
NEPHRON | 1992年 / 61卷 / 02期
关键词
ALUMINUM; IRON STORE; FERRITIN; DESFERRIOXAMINE; HEMODIALYSIS;
D O I
10.1159/000186864
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To evaluate the influence of body iron stores on the serum aluminum (Al) level, we studied the correlation between iron status (the serum ferritin, serum iron and transferrin saturation) and serum Al levels in 68 severely anemic hemodialysis patients. Among them, 36 underwent the desferrioxamine (DFO) mobilization test. These 68 patients were divided into three groups according to their serum ferritin level. The basal Al level in the patient group was 41.4 +/- 37.4-mu-g/l (control, 4.1 +/- 2.4-mu-g/l). The serum Al level after DFO infusion of the patient group was 111.1 +/- 86.8-mu-g/l. A significantly higher basal Al and peak Al level after DFO infusion were found in group 1 patients (serum ferritin < 300-mu-g/l) when compared to group 2 (serum ferritin 300-1,000-mu-g/l) and group 3 (serum ferritin > 1,000-mu-g/1) patients. A significant negative correlation between serum ferritin and basal serum Al (r = -0.544, p = 0.0001), as well as peak serum Al after DFO infusion (r = -0.556, p = 0.0001), was noted. Similarly, a negative relationship between serum Al (both basal and peak) and either serum iron or transferrin saturation was noted. However, there was no correlation between the serum Al level and the dosage of aluminum hydroxide. In conclusion, serum ferritin, serum iron and transferrin saturation were inversely correlated with serum Al in our hemodialysis patients. Iron deficiency may probably increase Al accumulation in these patients.
引用
收藏
页码:158 / 162
页数:5
相关论文
共 22 条
[1]   COMPARISON OF PARATHYROID-HORMONE ASSAYS WITH BONE HISTOMORPHOMETRY IN RENAL OSTEODYSTROPHY [J].
ANDRESS, DL ;
ENDRES, DB ;
MALONEY, NA ;
KOPP, JB ;
COBURN, JW ;
SHERRARD, DJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (05) :1163-1169
[2]  
BARTON JC, 1978, J LAB CLIN MED, V92, P536
[3]  
BROWN S, 1984, CLIN CHEM, V30, P1216
[4]  
CANNATA JB, 1984, P EUR DIAL TRANSPLAN, V21, P354
[5]   DIALYSIS OSTEODYSTROPHY - A STUDY INVOLVING 94 PATIENTS [J].
CHAN, YL ;
FURLONG, TJ ;
CORNISH, CJ ;
POSEN, S .
MEDICINE, 1985, 64 (05) :296-309
[6]  
DAVISON AM, 1982, LANCET, V2, P785
[7]   ORAL ALUMINUM ADMINISTRATION TO UREMIC, HYPERPARATHYROID, OR VITAMIN-D-SUPPLEMENTED RATS [J].
DRUEKE, T ;
LACOUR, B ;
TOUAM, M ;
BASILE, C ;
BOURDON, R .
NEPHRON, 1985, 39 (01) :10-17
[8]   CORRECTION OF THE ANEMIA OF END-STAGE RENAL-DISEASE WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN - RESULTS OF A COMBINED PHASE-I AND PHASE-II CLINICAL-TRIAL [J].
ESCHBACH, JW ;
EGRIE, JC ;
DOWNING, MR ;
BROWNE, JK ;
ADAMSON, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (02) :73-78
[9]  
FERNANDEZ MJ, 1990, KIDNEY INT, V37, P1612
[10]  
HODSMAN AB, 1985, J LAB CLIN MED, V106, P674